drugset / Trial / NCT01919697

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

NCT01919697

Phase 3 Completed 2370 enrolled Bausch Health Americas, Inc. Syneos Health · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).

Timeline

Start
2013-08
Primary completion
2016-01
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Plecanatide Peptide 3 mg Oral
Subject Plecanatide Peptide 6 mg Oral

Indications